Tight junction-associated signaling pathways modulate cell proliferation in uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 1, 2011, Pages 588-593

  Jayagopal, Ashwath ^a,b   Yang, Jin Long ^b   Haselton, Frederick R ^b,c   Chang, Min S ^b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID BINDING PROTEIN; OCCLUDIN; PROTEIN ZO1; BVES PROTEIN, HUMAN; CCAAT ENHANCER BINDING PROTEIN; CSDA PROTEIN, HUMAN; HEAT SHOCK PROTEIN; MEMBRANE PROTEIN; PHOSPHOPROTEIN; TRANSCRIPTION FACTOR; ZONULA OCCLUDENS-1 PROTEIN;

ARTICLE; BIOLUMINESCENCE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EPICARDIUM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TIGHT JUNCTION; TRANSCRIPTION REGULATION; TUMOR CELL LINE; UVEA MELANOMA; CELL CYCLE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; UVEA TUMOR; WESTERN BLOTTING;

BLOTTING, WESTERN; CCAAT-ENHANCER-BINDING PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENETIC VECTORS; HEAT-SHOCK PROTEINS; HUMANS; MELANOMA; MEMBRANE PROTEINS; PHOSPHOPROTEINS; SIGNAL TRANSDUCTION; TIGHT JUNCTIONS; TRANSCRIPTION FACTORS; TRANSFECTION; UVEAL NEOPLASMS;

EID: 79952461590     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5746     Document Type: Article

References (45)

1. Singh AD, Kivela T. The collaborative ocular melanoma study. Ophthalmol Clin North Am. 2005;18:129-142, ix.
2. Gamel JW, McLean IW. Quantitative analysis of the Callender classification of uveal melanoma cells. Arch Ophthalmol. 1977;95: 686-691.
3. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389-1398.
4. Folberg R, Pe'er J, Gruman LM, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol. 1992;23:1298-1305.
5. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205-7209.
6. Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 2006;66:4602-4609.
7. Lai K, Conway RM, Crouch R, Jager MJ, Madigan MC. Expression and distribution of MMPs and TIMPs in human uveal melanoma. Exp Eye Res. 2008;86:936-941.
8. Aijaz S, Balda MS, Matter K. Tight junctions: molecular architecture and function. Int Rev Cytol. 2006;248:261-298.
9. Kohler K, Louvard D, Zahraoui A. Rab13 regulates PKA signaling during tight junction assembly. J Cell Biol. 2004;165:175-180.
10. Tsukita S, Yamazaki Y, Katsuno T, Tamura A. Tight junction-based epithelial microenvironment and cell proliferation. Oncogene. 2008;27:6930-6938.
11. Lee JF, Zeng Q, Ozaki H, et al. Dual roles of tight junctionassociated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem. 2006;281:29190-29200.
12. Swisshelm K, Macek R, Kubbies M. Role of claudins in tumorigenesis. Adv Drug Deliv Rev. 2005;57:919-928.
13. Russ PK, Kupperman AI, Presley SH, Haselton FR, Chang MS. Inhibition of RhoA signaling with increased Bves in trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2010;51:223-230.
14. Kawaguchi M, Hager HA, Wada A, Koyama T, Chang MS, Bader DM. Identification of a novel intracellular interaction domain essential for Bves function. PLoS One. 2008;3:e2261.
15. Osler ME, Chang MS, Bader DM. Bves modulates epithelial integrity through an interaction at the tight junction. J Cell Sci. 2005;118: 4667-4678.
16. Ripley AN, Chang MS, Bader DM. Bves is expressed in the epithelial components of the retina, lens, and cornea. Invest Ophthalmol Vis Sci. 2004;45:2475-2483.
17. Knight RF, Bader DM, Backstrom JR. Membrane topology of Bves/Pop1A, a cell adhesion molecule that displays dynamic changes in cellular distribution during development. J Biol Chem. 2003;278: 32872-32879.
18. Smith TK, Hager HA, Francis R, Kilkenny DM, Lo CW, Bader DM. Bves directly interacts with GEFT, and controls cell shape and movement through regulation of Rac1/Cdc42 activity. Proc Natl Acad Sci U S A. 2008;105:8298-8303.
19. Osler ME, Smith TK, Bader DM. Bves, a member of the Popeye domain-containing gene family. Dev Dyn. 2006;235:586-593.
20. Wada AM, Reese DE, Bader DM. Bves: prototype of a new class of cell adhesion molecules expressed during coronary artery development. Development. 2001;128:2085-2093.
21. Reese DE, Zavaljevski M, Streiff NL, Bader D. bves: A novel gene expressed during coronary blood vessel development. Dev Biol. 1999;209:159-171.
22. Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta. 2009;1788:872-891.
23. Balda MS, Garrett MD, Matter K. The ZO-1-associated Y-box factor ZONAB regulates epithelial cell proliferation and cell density. J Cell Biol. 2003;160:423-432.
24. Balda MS, Matter K. The tight junction protein ZO-1 and an interacting transcription factor regulate ErbB-2 expression. EMBO J. 2000;19:2024-2033.
25. Sourisseau T, Georgiadis A, Tsapara A, et al. Regulation of PCNA and cyclin D1 expression and epithelial morphogenesis by the ZO-1-regulated transcription factor ZONAB/DbpA. Mol Cell Biol. 2006;26:2387-2398.
26. Albert DM, Ruzzo MA, McLaughlin MA, Robinson NL, Craft JL, Epstein J. Establishment of cell lines of uveal melanoma: methodology and characteristics. Invest Ophthalmol Vis Sci. 1984;25: 1284-1299.
27. Luyten GP, Naus NC, Mooy CM, et al. Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer. 1996;66:380-387.
28. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis. 1997;15: 509-518.
29. Verbik DJ, Murray TG, Tran JM, Ksander BR. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer. 1997;73:470-478.
30. Folberg R, Kadkol SS, Frenkel S, et al. Authenticating cell lines in ophthalmic research laboratories. Invest Ophthalmol Vis Sci. 2008;49:4697-4701.
31. Sun W, Zhou S, Chang SS, McFate T, Verma A, Califano JA. Mitochondrial mutations contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma. Clin Cancer Res. 2009;15:476-484.
32. Li G, Kim DH, Kim TD, et al. Protein-bound polysaccharide from Phellinus linteus induces G2/M phase arrest and apoptosis in SW480 human colon cancer cells. Cancer Lett. 2004;216:175-181.
33. Arai M, Sato H, Kobayashi H, et al. Selective inhibition of bleomycin- induced G2 cell cycle checkpoint by simaomicin alpha. Biochem Biophys Res Commun. 2004;317:817-822.
34. Nemeth Z, Szasz AM, Somoracz A, et al. Zonula occludens-1, occludin, and E-cadherin protein expression in biliary tract cancers. Pathol Oncol Res. 2009;15:533-539.
35. Orban E, Szabo E, Lotz G, et al. Different expression of occluding and ZO-1 in primary and metastatic liver tumors. Pathol Oncol Res. 2008;14:299-306.
36. Hoover KB, Liao SY, Bryant PJ. Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am J Pathol. 1998;153:1767-1773.
37. Martin TA, Watkins G, Mansel RE, Jiang WG. Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer. 2004;40: 2717-2725.
38. Ohtani S, Terashima M, Satoh J, et al. Expression of tight-junctionassociated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival. Gastric Cancer. 2009;12:43-51.
39. Balda MS, Matter K. Tight junctions and the regulation of gene expression. Biochim Biophys Acta. 2009;1788:761-767.
40. Matter K, Balda MS. Epithelial tight junctions, gene expression and nucleo-junctional interplay. J Cell Sci. 2007;120:1505-1511.
41. Nie M, Aijaz S, Leefa Chong San IV, Balda MS, Matter K. The Y-box factor ZONAB/DbpA associates with GEF-H1/Lfc and mediates Rho-stimulated transcription. EMBO Rep. 2009;10:1125-1131.
42. Pannequin J, Delaunay N, Darido C, et al. Phosphatidylethanol accumulation promotes intestinal hyperplasia by inducing ZONABmediated cell density increase in response to chronic ethanol exposure. Mol Cancer Res. 2007;5:1147-1157.
43. Kavanagh E, Buchert M, Tsapara A, et al. Functional interaction between the ZO-1-interacting transcription factor ZONAB/DbpA and the RNA processing factor symplekin. J Cell Sci. 2006;119: 5098-5105.
44. Tsapara A, Matter K, Balda MS. The heat-shock protein Apg-2 binds to the tight junction protein ZO-1 and regulates transcriptional activity of ZONAB. Mol Biol Cell. 2006;17:1322-1330.
45. Lima WR, Parreira KS, Devuyst O, et al. ZONAB promotes proliferation and represses differentiation of proximal tubule epithelial cells. J Am Soc Nephrol. 2010;21:478-488.